← Leaderboards
Jeff T Hutchins
Inhalon Biopharma, Inc.
$11,797,728
Attributed
$11,797,728
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.7M · FY2022–25$5M$3.8M$2.5M$1.3M$0
'22
'23
'24
'25
Funding mix
By agency
NIH$11,797,728 · 7
By mechanism
R44$9,192,272 · 6
SB1$2,605,456 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Clinical Research”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Angee Greer · Ppd Development Lp$82,531,927
- Gary Mays · Axle Informatics, Llc$59,196,540
- Mari Ostendorf · University Of Washington$51,931,230
- Jessica Ellis · Technical Resources International, Inc.$43,038,640
- Jessica Holden · Technical Resources International, Inc.$37,843,443
Research focus
Clinical ResearchViralInfectionClinicInhalationMonoclonal AntibodiesDoseHospitalizationMucous Body SubstancePhase 1 StudyCross ReactivityImmunocompromised HostViral Load ResultNebulizerVirionBronchiolitisAntibody TherapyCyclic GmpTissuesVirusNeutralizing Monoclonal AntibodiesCellsMucinsLung
Grant awards (12)
IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection$1,024,879
R44 · FY2025 · AI · contact PI
SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections$1,023,875
R44 · FY2025 · AI · contact PI
Development of IN-003PI as passive immunization against human metapneumovirus infection$1,013,468
R44 · FY2025 · AI · contact PI
IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A$1,013,003
R44 · FY2025 · AI · contact PI
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus$608,832
SB1 · FY2025 · AI · contact PI
SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections$1,024,986
R44 · FY2024 · AI · contact PI
IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection$1,024,942
R44 · FY2024 · AI · contact PI
Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV$1,024,926
R44 · FY2024 · AI · contact PI
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus$996,814
SB1 · FY2024 · AI · contact PI
IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus$1,018,961
R44 · FY2023 · AI · contact PI
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus$999,810
SB1 · FY2023 · AI · contact PI
IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus$1,023,232
R44 · FY2022 · AI · contact PI